occurs in has participant quality has disease treated with drug MEGESTROL GEMCITABINE TOPOTECAN FLUCYTOSINE CYTARABINE CHLORAMBUCIL CARBOPLATIN ZIDOVUDINE ALTRETAMINE DOXORUBICIN GANCICLOVIR PENTAMIDINE ALDESLEUKIN FOSCARNET TENIPOSIDE PACLITAXEL BICALUTAMIDE DOCETAXEL CAPECITABINE INFLIXIMAB BEXAROTENE IMATINIB VALGANCICLOVIR OXALIPLATIN BORTEZOMIB EMTRICITABINE LENALIDOMIDE NELARABINE NILOTINIB CABAZITAXEL ERIBULIN CARFILZOMIB mature T-cell and NK-cell lymphoma Cytomegalovirus retinitis prostate cancer prostate carcinoma lymphoblastic leukemia chronic lymphocytic leukemia pneumocystosis cryptococcosis lymphocytic choriomeningitis lung cancer breast cancer colon cancer ovarian cancer dermatofibrosarcoma protuberans retinitis cervical cancer renal cell carcinoma myelodysplastic/myeloproliferative neoplasm human immunodeficiency virus infectious disease acute T cell leukemia chronic myeloid leukemia Kaposi's sarcoma anorexia nervosa Crohn's disease gastrointestinal stromal tumor colorectal cancer multiple myeloma acute lymphocytic leukemia Elderly Child Newborn Adult anemia AE 10002034 10002272 MP: MP_0001577 CTCAE: E10010 a hematopoietic system AE which has an outcome of anemia, which is less than normal levels of red blood cells and/or hemoglobin within red blood cells, or volume of packed red blood cells in the bloodstream, resulting in insufficient oxygenation of tissues and organs NCIt: C2869 WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001586/ anaemia AE hematopoietic system AE AE severity G1 AE severity G2 AE severity G3 AE severity G4 AE severity G5